Storm Therapeutics discovers and develops small molecule drugs that target RNA-modifying enzymes, for treatment of cancer. Several large families of RNA-modifying enzymes have been identified that impact key biological processes by changing the activity of RNA through catalysing epigenetic RNA modifications. Advances in the understanding of RNA modification and its role in the development of cancer offer the prospect of exploring novel therapeutic targets and potential discovery and development of first-in-class products. STORM is working in this new field.